share_log

Truist Securities Reiterates Buy on PROCEPT BioRobotics, Lowers Price Target to $74

Benzinga ·  Aug 2 21:16  · Ratings

Truist Securities analyst Richard Newitter reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $79 to $74.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment